Using advanced CRISPR technology to edit genes in the brain for Alzheimer's treatment
Nanoformulated CRISPR Ribonucleoproteins for Ultrasound-Facilitated Brain Gene Editing
This study is exploring a new way to help people with Alzheimer's by using tiny gene-editing tools and sound waves to deliver treatment directly to the brain, making it safer and more effective for those affected by the disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10727386 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat Alzheimer's disease by utilizing nanoformulated CRISPR ribonucleoproteins combined with ultrasound technology to facilitate gene editing in the brain. The study aims to overcome the challenges of delivering CRISPR components effectively to the brain, which is crucial for addressing neuronal degeneration disorders. By creating a library of lipid-coated CRISPR components and optimizing methods to open the blood-brain barrier, the research seeks to enhance the safety and efficacy of gene therapy for Alzheimer's patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related neurodegenerative disorders.
Not a fit: Patients with early-stage Alzheimer's or those without a confirmed diagnosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer gene therapies for patients suffering from Alzheimer's disease.
How similar studies have performed: While gene editing technologies are emerging, this specific approach using nanoformulated CRISPR for brain applications is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Lao, Yeh-Hsing — State University of New York at Buffalo
- Study coordinator: Lao, Yeh-Hsing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.